Overall, our results demonstrate that CEA is the major carrier of SLex antigens in aggressive gastric carcinomas and highlights the combination of CEA and SLex for potential clinical applications in gastric cancer prognosis. This evidence concerns the gene CEACAM5 and gastric cancer.